Press Release

BASEL, Switzerland, May 9, 2023 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that senior members of its Management Team will present at BioEquity Europe taking place May 14-16, 2023, in Dublin, Ireland. Noema management will provide an update on its clinical development activities and outline anticipated […]

Oversubscribed financing to support continued development of its diversified pipeline focused on central nervous system disorders Nanna Lüneborg, General Partner at Forbion and Rachel Mears, Partner at Jeito Capital to join Board of Directors Multiple Phase 2b trials in orphan and mainstream CNS indications continue to advance BASEL, Switzerland, March 7, 2023 – Noema Pharma,

BASEL, Switzerland and BOSTON, Massachusetts, January 5, 2023 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members of the Management Team will attend and present at the 41st Annual J.P. Morgan Healthcare Conference taking place on January 9-12, 2023 in San Francisco, CA. Presentation DetailsDate: Tuesday 10

BASEL, Switzerland, October 18, 2022 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia (TN). Fast Track designation aims at facilitating the development

Study to validate the novel Patient-Reported Electronic Diary designed to more efficiently and accurately measure disease burden associated with trigeminal neuralgia LIBRATN (NOE-101 Phase 2/3 study in Trigeminal Neuralgia) is on track to report top-line data in H1 2024 BASEL, Switzerland/ Boston, MA, September 6, 2022 – Noema Pharma, a clinical-stage biotech company targeting debilitating

Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 2023 BASEL, Switzerland / Boston, MA, August 4, – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announced the dosing of the first patient

Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 2023 BASEL, Switzerland / Boston, MA, June 27, 2022 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces the US Food and Drug Administration (FDA)

BASEL, Switzerland, May 6, 2022 – Noema Pharma, a Swiss clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications, today announces Luigi Costa, Chief Executive Officer, and Michael Gutch, Chief Financial Officer, will attend and present at two upcoming investor events: BioEquity Europe, Milan, Italy and virtually, May 16-18, 2022 Presentation on Tuesday 17 May

BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer. Dr. Gutch has extensive experience in the healthcare and pharmaceutical industries and venture capital investment. He served as Executive Director of Corporate Development

Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inihibitor NOE-101 in trigeminal neuralgia